TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04907825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral anticoagulant
Description: Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with ACC/AHA/HRS Guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant
Description: Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with ACC/AHA/HRS Guidelines
Study: NCT06035952

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D topographical scan
Description: Subjects will undergo a quick, radiation-free, no contact 3D scan using a smartphone.
Study: NCT04779216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab Prefilled Syringe
Description: Romosozumab 210mg Injection monthly for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Injection monthly for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate 70Mg Tab
Description: Alendronate 70mg PO weekly starting at 12 months through 24 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alendronate 70Mg Tab
Description: Alendronate 70mg PO weekly starting at 12 months through 24 months.
Study: NCT05172271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagPro TMS Stimulator and coil
Description: TMS measurements of cortical excitability pre and post study intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thymatron(R) System IV
Description: The Thymatron(R) System IV (Somatics LLC, Venice, FL, USA) is an FDA 510(k)-cleared ECT device. For TESt, we will be using it in a non FDA-approved manner--stimulating without intending to induce seizures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging Scanner
Description: Conventional MRI studies in this protocol are considered non-significant risk (NSR) devices. While operated in research mode, the MRI will be under the International Electrotechnical Commission (IEC) 60601-2-33 First Level Controlled Operating Mode, which allows for research pulse sequences to be used within the FDA/IEC safety limits for MRI devices.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: ECT device without stimulation
Description: Anesthesia alone
Study: NCT05139589

Intervention type: OTHER
Intervention: None, observational
Description: Patients with infective endocarditis who do and do not undergo valve surgery compared with patientswithout endocarditis, who are operated on with similar valve surgery

Intervention type: OTHER
Intervention: None, observational
Description: Patients with infective endocarditis who do and do not undergo valve surgery compared with patientswithout endocarditis, who are operated on with similar valve surgery

Intervention type: OTHER
Intervention: None, observational
Description: Patients with infective endocarditis who do and do not undergo valve surgery compared with patientswithout endocarditis, who are operated on with similar valve surgery
Study: NCT05412511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MB-TB
Description: Training exercises with throwing a medicine ball will be performed for 30 seconds and the training volume will be consisted of 1 repetition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MB-NTB
Description: Training exercises without throwing a medicine ball will be performed for 30 seconds and the training volume will be consisted of 1 repetition.
Study: NCT03595150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Diclofenac rectally given before the ERCP to prevent pancreatitis
Study: NCT06102512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-LOXO-783
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-783
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-LOXO-783
Description: Administered IV
Study: NCT05594485

Intervention type: DEVICE
Intervention: Carebot AI CXR
Description: Carebot AI CXR is a deep learning-based software that assists radiologists in the interpretation of chest radiographs in posterior-anterior (PA) or anterior-posterior (AP) projections. The solution with artificial intelligence automatically detects abnormality based on visual patterns for the following findings: atelectasis, consolidation, cardiomegaly, mediastinal widening, pneumoperitoneum, pneumothorax, pulmonary edema, pulmonary lesion, bone fracture, hilar enlargement, subcutaneous emphysema, and pleural effusion.
Study: NCT06289894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRY805 injection
Description: BRY805 will be administered via IV infusion every 3 weeks. , Six dose levels of 0.3, 1, 3, 9,18 and 30 mg/kg will be tested
Study: NCT05489198

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cataract surgery with Centurion phacoemulsification system
Description: Cataract surgery performed with the Centurion phacoemulsification system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cataract surgery with Quatera 700 phacoemulsification system
Description: Cataract surgery performed with the Quatera 700 phacoemulsification system
Study: NCT06361030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib combined with gemcitabine plus nab-paclitaxel
Description: Surufatinib capsules: oral, once daily. Combination treatment period: 200 mg each time, every 4 weeks for a treatment cycle(Q4W). If all the chemotherapy drugs were stopped during the maintenance treatment period, only surufatinib was left, the dose of Surufatinib could be increased to 300 mg per dose according to the patient\&#39;s condition.~Gemcitabine: iv, 1000 mg/m2, days 1, 8, and 15 of each treatment cycle, Q4W. Paclitaxel (albumin-bound), iv, 125mg/m2, on days 1, 8 and 15 of each treatment cycle, Q4W.~All they will be used until disease progression, death, intolerable toxicity, initiation of new antineoplastic therapy, withdrawal of consent, loss to follow-up, or any other protocol-specified event requiring treatment discontinuation or study closure, whichever occurred first.~But If surgical resection was performed, they will be only maintained for 6 months after surgery.
Study: NCT04881110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Patients in this arm will receive one daily subcutaneous injection of liraglutide. The starting dose is 0.6 mg/dl per day. The dose has to be increased to 1.2 mg/dl per day after the first week of treatment and to 1.8 mg/dl after the second one.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Patients in this arm will be strictly monitored for atherosclerosis major risk factors, such as hypertension and dyslipidemia, and treated according to current clinical practice.
Study: NCT05135091

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NRTX-1001
Description: Biological: NRTX-1001 is an experimental neural cell therapy product candidate derived from an allogeneic human embryonic stem cell line. The stem cells were converted into inhibitory nerve cells that produce GABA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NRTX-1001
Description: Biological: NRTX-1001 is an experimental neural cell therapy product candidate derived from an allogeneic human embryonic stem cell line. The stem cells were converted into inhibitory nerve cells that produce GABA.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Sham Comparator.
Study: NCT05176392

Intervention type: DEVICE
Group type: OTHER
Intervention: Active rTMS
Description: Active rTMS will be given at the left dorsolateral prefrontal cortex with a double blind TMS coil.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS
Description: Active rTMS will be given at the left dorsolateral prefrontal cortex with a double blind TMS coil.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Headache Management Therapy
Description: Therapy will be provided on headache management.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Headache Management Therapy
Description: Therapy will be provided on headache management.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham rTMS will be given at the left dorsolateral prefrontal cortex. All parameters of the treatment will appear identical to the active treatment, with only the rTMS coil used to administer the treatment flipped 180 degrees to prevent stimulation.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham rTMS
Description: Sham rTMS will be given at the left dorsolateral prefrontal cortex. All parameters of the treatment will appear identical to the active treatment, with only the rTMS coil used to administer the treatment flipped 180 degrees to prevent stimulation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Headache Education Control
Description: In the control, educational sessions on headaches will be provided.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Headache Education Control
Description: In the control, educational sessions on headaches will be provided.
Study: NCT04248322

Intervention type: BEHAVIORAL
Intervention: Semi-structured interview
Description: Using iterative, semi-structured interviews or focus groups to explore the lived experience with CC and usual customary care (UCC) of catheter users with NLUTD and their caretakers to generate user-defined themes regarding bladder function and catheter-related barriers and the daily impacts on one's life.
Study: NCT06474143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apneal device
Description: Patients will wear a smartphone with the Apneal Application on their chest, while they perform polysomnography
Study: NCT06449677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLet Bionic Pancreas System (BP)
Description: The iLet Bionic Pancreas System (BP) consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls insulin delivery based on glucose values obtained by communicating with a CGM sensor.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iLet Bionic Pancreas System (BP)
Description: The iLet Bionic Pancreas System (BP) consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls insulin delivery based on glucose values obtained by communicating with a CGM sensor.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (UC)
Description: Usual Care consists in the participant existing insulin therapy (prior to enrollment) in conjunction with a study CGM. Existing insulin therapies are defined as multiple daily injections of insulin (MDI) or use of an insulin pump.
Study: NCT06540443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPB-2043 of 0.5 mg/kg
Description: Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPB-2043 of 1.0 mg/kg
Description: Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPB-2043 of 2.0 mg/kg
Description: Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPB-2043 of 3.0 mg/kg
Description: Participants will undergo MRI scans without the administration of a contrast agent (unenhanced MRI) and IV-infused MPB-2043 for 1 hour.
Study: NCT06497374

Intervention type: DRUG
Group type: OTHER
Intervention: Efgartigimod Alfa Injection
Description: Efgartigimod+IVMP; IVMP; Efgartigimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efgartigimod Alfa Injection
Description: Efgartigimod+IVMP; IVMP; Efgartigimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose intravenous methylprednisolone
Description: Efgartigimod+IVMP; IVMP; Efgartigimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose intravenous methylprednisolone
Description: Efgartigimod+IVMP; IVMP; Efgartigimod
Study: NCT06521151

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: egg based diet
Description: egg based diet and audio based nutrition education group (arm-1), egg based diet alone group (arm-2), and audio based nutrition education alone group (arm- 3).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: egg based diet
Description: egg based diet and audio based nutrition education group (arm-1), egg based diet alone group (arm-2), and audio based nutrition education alone group (arm- 3).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: egg based diet
Description: egg based diet and audio based nutrition education group (arm-1), egg based diet alone group (arm-2), and audio based nutrition education alone group (arm- 3).
Study: NCT04830215

Intervention type: DRUG
Group type: OTHER
Intervention: Brexpiprazole
Description: Oral brexpiprazole tablets as adjunctive therapy to ADT
Study: NCT05442723

Intervention type: PROCEDURE
Group type: OTHER
Intervention: On-Pump CABG
Description: coronary artery grafting by using cardiopulmonary bypass machine

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Off-Pump CABG
Description: coronary artery grafting by beating heart technique
Study: NCT05091918

Intervention type: DEVICE
Group type: OTHER
Intervention: MotionSense
Description: MotionSense Wearable: Remote patient monitoring
Study: NCT06527703

Intervention type: OTHER
Intervention: no intervention
Description: Patients have to answer a questionnaire. The following data will be recorded:~Patient Number:~Informed Consent: ☐ yes ☐ no~Screening for eligibility Age \>/= 18 years: ☐ yes ☐ no Gender: ☐ M ☐ F Patient undergoing elective procedure: ☐ yes ☐ no~Time of arrival in the operating room _________________~Procedure:~General surgery ☐ Orthopaedic surgery ☐ Neurosurgery ☐ Cardiac surgery ☐ Vascular ☐ Urology ☐ ENT/ dental/ maxillo-facial ☐ Obstetrics and Gynaecology surgery ☐ Ophthalmic surgery ☐ Non-operating room anaesthesia ☐ Endoscopy ☐ Other ____________________~Type of Anaesthesia (choose 1):~GA ☐ Sedation ☐ Regional ☐~Date and Time at which clear fluids were last consumed:_______________________

Intervention type: OTHER
Intervention: no intervention
Description: Patients have to answer a questionnaire. The following data will be recorded:~Patient Number:~Informed Consent: ☐ yes ☐ no~Screening for eligibility Age \>/= 18 years: ☐ yes ☐ no Gender: ☐ M ☐ F Patient undergoing elective procedure: ☐ yes ☐ no~Time of arrival in the operating room _________________~Procedure:~General surgery ☐ Orthopaedic surgery ☐ Neurosurgery ☐ Cardiac surgery ☐ Vascular ☐ Urology ☐ ENT/ dental/ maxillo-facial ☐ Obstetrics and Gynaecology surgery ☐ Ophthalmic surgery ☐ Non-operating room anaesthesia ☐ Endoscopy ☐ Other ____________________~Type of Anaesthesia (choose 1):~GA ☐ Sedation ☐ Regional ☐~Date and Time at which clear fluids were last consumed:_______________________
Study: NCT05562089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A Paclitaxel Drug-Coated Balloon
Description: Size: 2.0mm-4.0mm x 15-30mm Coated drug: Prevail TM
Study: NCT06242951

Intervention type: DIAGNOSTIC_TEST
Intervention: VO2 max assessment
Description: Measurement of the maximum oxygen consumption (VO2max) by a cardiopulmonary exercise test (CPET)

Intervention type: DIAGNOSTIC_TEST
Intervention: VO2 max assessment
Description: Measurement of the maximum oxygen consumption (VO2max) by a cardiopulmonary exercise test (CPET)
Study: NCT06647511

Intervention type: DEVICE
Intervention: Nokia-Withings BPM Connect Blood Pressure Monitor
Description: At-home blood pressure (BP) measurements will be weekly via a blood pressure cuff (e.g., Nokia-Withings BPM (Beats per Minute) Connect), with measurements being manually entered into the study specific smartphone app.

Intervention type: DEVICE
Intervention: Smartwatch Devices
Description: Passive continuous collection of digital data (e.g., daily heart rate trends, activity levels, sleep measurements) for exploratory outcomes will occur via Apple Watches and Fitbit Versa 3s, which are synced to a smartphone application.
Study: NCT05349968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipovirtide for injection
Description: Multiple dosing of Lipovirtide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipovirtide for injection
Description: Multiple dosing of Lipovirtide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipovirtide for injection
Description: Multiple dosing of Lipovirtide
Study: NCT04051866

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment: Scaling and root planing (SRP)
Description: Removal of dental plaque and dental calculus from the surface of a tooth, from the surface of a tooth apical to the gingival margin accumulated in periodontal pockets, or from the surface coronal to the gingival margin.

Intervention type: OTHER
Group type: OTHER
Intervention: Oral hygiene instructions
Description: Education for individual health regarding peridontal disease and its association with diabetes, as well as oral hygiene instructions that include the modified Bass technique, use of interproximal brushes and dental floss

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral hygiene instructions
Description: Education for individual health regarding peridontal disease and its association with diabetes, as well as oral hygiene instructions that include the modified Bass technique, use of interproximal brushes and dental floss
Study: NCT05378880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural intervention bundle to optimise antibiotic use and reduce the risk of human-to-human or environmental-animal-human transmission
Description: The study teams will work with communities and authorities to develop, implement and evaluate a multifaceted intervention bundle that will optimise antibiotic use and reduce the risk of human-to-human or environmental-animal-human transmission, by targeting the general public (including farmers) and medicine stores.
Study: NCT04755920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGM-101
Description: Fluorescence-guided surgery
Study: NCT05778097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide 60mg Tab
Description: Apalutamide 60Mg Tab (4 x 60 mg) once daily on days 1-28 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy(ADT)
Description: The choice of ADT will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
Study: NCT05464069

Intervention type: DEVICE
Intervention: Nerivio
Description: Nerivio is a Remote Electrical Neuromodulation (REN) device for the acute treatment of migraines. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application
Study: NCT05950490

Intervention type: DRUG
Intervention: Intravitreal injection of methotrexate
Description: Intravitreal injection of methotrexate:400ug/0.1mL，Once a week\*4 weeks → Once every two weeks\*4 weeks → once a month \*10 times(16 times a year)~Systemic therapy:~Induction period:（Zanubrutinib + Rituximab，ZR） (28 days/cycle) x 6 cycles:Rituximab iv375mg/m2 D1, Zanubrutinib 160mg bid D1-D21; Maintenance treatment:Zanubrutinib 160mg bid x 2 years

Intervention type: DRUG
Intervention: Intravitreal injection of methotrexate
Description: Intravitreal injection of methotrexate:400ug/0.1mL，Once a week\*4 weeks → Once every two weeks\*4 weeks → once a month \*10 times(16 times a year)~Systemic therapy:~Induction period:（Zanubrutinib + Rituximab，ZR） (28 days/cycle) x 6 cycles:Rituximab iv375mg/m2 D1, Zanubrutinib 160mg bid D1-D21; Maintenance treatment:Zanubrutinib 160mg bid x 2 years
Study: NCT05912088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Subjects will participate in groups of about 14 to implement the program.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Subjects will receive the usual care advice
Study: NCT06464692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion
Study: NCT06150924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD
Description: Period 1 - Lorundrostat 25mg QD + SGLT2i QD 4 weeks; Washout - Placebo QD + SGLT2i QD 4 weeks; Period 2 - Placebo QD + SGLT2i QD 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD
Description: Period 1 - Placebo QD + SGLT2i QD 4 weeks; Washout - Placebo QD + SGLT2i QD 4 weeks; Period 2 - Lorundrostat 25mg + SGLT2i QD 4 weeks
Study: NCT04683315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX Treatment Regimen
Description: This therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX Treatment Regimen
Description: This therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX Treatment Regimen
Description: This therapy will be 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Nab-paclitaxel Treatment Regimen
Description: This regimen will be nab-paclitaxel and gemcitabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Nab-paclitaxel Treatment Regimen
Description: This regimen will be nab-paclitaxel and gemcitabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Nab-paclitaxel Treatment Regimen
Description: This regimen will be nab-paclitaxel and gemcitabine.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: 50.4 Gy in 28 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: 50.4 Gy in 28 fractions.
Study: NCT05599048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-Pyruvate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-Pyruvate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Imaging procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Imaging procedure